Last reviewed · How we verify
Zhuhai Trinomab Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
3 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Adsorbed tetanus vaccine | Adsorbed tetanus vaccine | marketed | ||||
| TNM001 | TNM001 | phase 3 | Trispecific monoclonal antibody | Oncology | ||
| TNM002 | TNM002 | phase 3 | PD-1 inhibitor | PD-1 | Oncology | |
| HTIG | HTIG | phase 3 | TIGIT inhibitor (monoclonal antibody) | TIGIT | Oncology |
Therapeutic area mix
- Oncology · 3
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- ASLAN Pharmaceuticals · 1 shared drug class
- ATGC Co., Ltd. · 1 shared drug class
- Addpharma Inc. · 1 shared drug class
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- Akeso · 1 shared drug class
- Amgen · 1 shared drug class
- Asahi Kasei Pharma Corporation · 1 shared drug class
- 3D Medicines (Sichuan) Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Zhuhai Trinomab Pharmaceutical Co., Ltd.:
- Zhuhai Trinomab Pharmaceutical Co., Ltd. pipeline updates — RSS
- Zhuhai Trinomab Pharmaceutical Co., Ltd. pipeline updates — Atom
- Zhuhai Trinomab Pharmaceutical Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Zhuhai Trinomab Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zhuhai-trinomab-pharmaceutical-co-ltd. Accessed 2026-05-17.